Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- EXAS +15.9%, (sees Q4 revs above consensus) TTOO +7.5%, GPN +5.1%, PTCT +4.2%, VNDA +3.9%, FRAN +3.2%,SPNE +2%, PME +1.7%, NUVA +1.4%, VLRS +1.1%
M&A news:
- MSTX +122.5% (signs merger agreement with privately held Savara Inc )
- MACK +35.8% (concludes strategic review; Ipsen (IPSEY) to Acquire Oncology Assets from Merrimack for $575 mln cash; up to $450 mln in additional regulatory approval-based milestone payments
Select metals/mining stocks trading higher: KGC +5.4%, VALE +4%, AUY +3.2%, GFI +2.8%, MUX +2.3%, GG +2.3%,AG +2.3%, GDX +2.2%, SLW +2%, ABX +1.9%, NEM +1.8%, AKS +1.1%
Other news:
- ADMS +7.2% (prepares for potential approval and launch of ADS-5102 for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease in 2017)
- ARWR +7.1% (issues response to new minority shareholder announcement by Silence Therapeutics plc; no discussions about any potential transaction)
- KERX +6.3% (provides business update; sees Q4 revs above consensus)
- EBIO +5.2% (provides upcoming milestones in slide presentation)
- CTIC +4.8% (provides 2017 key objectives)
- MDCO +4.2% (presents compelling safety and efficacy data from Day 180 interim analysis for ORION-1 Phase 2 Study of Inclisiran )
- EXEL +3.1% (announced today that Genentech (RHHBY) has withdrawn its counterclaim against Exelixis in the ongoing JAMS arbitration )
- ARLZ +1.8% (enters into a rebate agreement with Express Scripts (ESRX))
Analyst comments:
- JD +2.6% (upgraded to Overweight from Neutral at JP Morgan)
- BIDU +0.7% (upgraded to Neutral from Underweight at JP Morgan)